MCD
52
3
AXP
63
3
HPQ
55
3
BK
60
2
KR
50
5
MCO
67
3
PRU
39
3
ED
39
8
PVH
58
5
IRM
33
5
DTE
49
16
DFS
64
4
AIZ
61
5
CHD
34
7
EMC
30
-26
CCL
68
6
FOX
71
3
PFE
37
4
FOXA
67
5
CTSH
55
3
MCD
52
3
AXP
63
3
HPQ
55
3
BK
60
2
KR
50
5
MCO
67
3
PRU
39
3
ED
39
8
PVH
58
5
IRM
33
5
DTE
49
16
DFS
64
4
AIZ
61
5
CHD
34
7
EMC
30
-26
CCL
68
6
FOX
71
3
PFE
37
4
FOXA
67
5
CTSH
55
3
Financhill
Back

Akoya Biosciences 10K Form

Sell
15

AKYA
Akoya Biosciences

Last Price:
$2.49
Seasonality Move:
-6.47%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive AKYA News And Ratings

See the #1 stock for the next 7 days that we like better than AKYA

AKYA Financial Statistics

Sales & Book Value

Annual Sales: $96.6M
Cash Flow: $-9.7M
Price / Cash Flow: 0
Annual Sales: $0.28
Price / Book: 9.02

Profitability

EPS (TTM): -1.18000
Net Income (TTM): $-58M
Gross Margin: $56.3M
Return on Equity: -157.22%
Return on Assets: -36.87%

Akoya Biosciences Earnings Forecast

Key Akoya Biosciences Financial Ratios

  • The Gross Profit Margin over the past 5 years for AKYA is 58.27%.
  • The Selling, General & Administrative Expenses for AKYA have been equal to 85.25% of Gross Profit Margin.
  • The Research & Development expenses have been 22.65% of Revenue.
  • The Interest Expense is -13.84% of Operating Income.
  • The Net Earning history of AKYA is -65.53% of Total Revenues.
  • Per Share Earnings over the last 5 years have been positive in 1 years.

Akoya Biosciences Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Life Sciences Tools & Services
Sector: Health Care
Current Symbol: AKYA
Website: akoyabio.com

Debt

Debt-to-Equity Ratio: 5.57
Current Ratio: 2.75
Quick Ratio: 1.74

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

AKYA Technical Analysis vs Fundamental Analysis

Sell
15
Akoya Biosciences (AKYA) is a Sell

Is Akoya Biosciences a Buy or a Sell?

  • Akoya Biosciences stock is rated a Sell
    The current Akoya Biosciences [AKYA] share price is $2.48. The Score for AKYA is 15, which is 70% below its historic median score of 50, and infers higher risk than normal.